High-grade dysplasia in patients with Barrett esophagus Advocacy Hub | UniteRare

At a Glance

Live from database

💊

Regulatory Watchboard

1 event

Aug 2003

Photofrin: FDA approved

For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for High-grade dysplasia in patients with Barrett esophagus.
Check the disease page for updates →

Approved Treatments

2 FDA-approved

Photofrin

(porfimer)Orphan drug

Axcan Scandipharm Inc.

Approved Aug 2003FDA label ↗

WEGOVY

(SEMAGLUTIDE)standard

Novo Nordisk

GLP-1 Receptor Agonist [EPC]

12.1 Mechanism of Action Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for High-grade dysplasia in patients with Barrett esophagus.
Search all trials →

Search clinical trials for High-grade dysplasia in patients with Barrett esophagus →

Recent News & Research

1 article

BREAKINGFDAMar 19, 2026

FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.

Read ↗

Browse all High-grade dysplasia in patients with Barrett esophagus news →